He Ya-Zhou, Chi Xiao-Sa, Zhang Yuan-Chuan, Deng Xiang-Bing, Wang Jia-Rong, Lv Wen-Yu, Zhou Yan-Hong, Wang Zi-Qiang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, People's Republic of China.
Tumour Biol. 2014 Jan;35(1):675-87. doi: 10.1007/s13277-013-1093-4. Epub 2013 Aug 27.
A number of studies have investigated the association between NBS1 Glu185Gln (rs1805794, E185Q) polymorphism and cancer risk, but the results remained controversial. Previous meta-analysis found a borderline significant impact of this polymorphism on cancer risk; however, the result might be relatively unreliable due to absence of numerous newly published studies. Thus, we conducted an updated meta-analysis. A systematic search was performed in PubMed and Embase databases until April 9, 2013. The odds ratios were pooled by the fixed-effects/random-effects model in STATA 12.0 software. As a result, a total of 48 case-control studies with 17,159 cases and 22,002 controls were included. No significant association was detected between the Glu185Gln polymorphism and overall cancer risk. As to subgroup analysis by cancer site, the results showed that this polymorphism could increase the risk for leukemia and nasopharyngeal cancer. Notably, the Glu185Gln polymorphism was found to be related to increased risk for urinary system cancer, but decreased risk for digestive system cancer. No significant associations were obtained for other subgroup analyses such as ethnicity, sample size and smoking status. In conclusion, current evidence did not suggest that the NBS1 Glu185Gln polymorphism was associated with overall cancer risk, but this polymorphism might contribute to the risk for some specific cancer sites due to potential different mechanisms. More well-designed studies are imperative to identify the exact function of this polymorphism in carcinogenesis.
多项研究探讨了NBS1基因Glu185Gln（rs1805794，E185Q）多态性与癌症风险之间的关联，但结果仍存在争议。先前的荟萃分析发现该多态性对癌症风险有临界显著影响；然而，由于缺乏众多新发表的研究，该结果可能相对不可靠。因此，我们进行了一项更新的荟萃分析。在PubMed和Embase数据库中进行了系统检索，直至2013年4月9日。采用STATA 12.0软件中的固定效应/随机效应模型合并比值比。结果，共纳入48项病例对照研究，包括17159例病例和22002例对照。未检测到Glu185Gln多态性与总体癌症风险之间存在显著关联。按癌症部位进行亚组分析时，结果显示该多态性可增加白血病和鼻咽癌的风险。值得注意的是，发现Glu185Gln多态性与泌尿系统癌症风险增加有关，但与消化系统癌症风险降低有关。在种族、样本量和吸烟状况等其他亚组分析中未获得显著关联。总之，目前的证据并不表明NBS1 Glu185Gln多态性与总体癌症风险相关，但由于潜在的不同机制，该多态性可能导致某些特定癌症部位的风险增加。需要更多设计良好的研究来确定该多态性在致癌过程中的确切作用。
